Evaluation of febuxostat initiation during an acute gout attack: A prospective, randomized clinical trial

Ruixia Sun,Jie Lu,Hui Li,Xiaoyu Cheng,Ying Xin,Changgui Li
DOI: https://doi.org/10.1016/j.jbspin.2020.03.017
IF: 5.263
2020-10-01
Joint Bone Spine
Abstract:<p>Objective: Urate-lowering treatment (ULT) is recommended in gout management. However, initiation of ULT during an acute gout flare is still inconclusive. This study aimed to evaluate the efficacy and safety of the ULT febuxostat administered at initiation of an acute gout attack.</p><p>Methods: A prospective randomized controlled clinical trial was conducted for 12 weeks in primary gout patients who were admitted with acute gout attacks. Subjects were randomly assigned to the febuxostat group in which febuxostat, 40 mg daily, was administered in the primary care setting for attacks, or to the control group in which febuxostat, 40 mg daily, was administered after the attacks. All patients received adequate anti-inflammatory and analgesic therapies. Serum urate (SU) levels were monitored throughout the study. Pain, measured using a visual analogue scale (VAS), and gout recurrence rate were used as primary outcomes. Flare-related inflammation biomarkers were selected as secondary outcomes.</p><p>Results: Fifty-two patients completed the study (febuxostat group: n = 28; control group: n = 24). No significant differences were detected in VAS scores between the two groups over the first 14-day observation period (P &gt; 0.05). Administration of febuxostat decreased SU levels significantly during the first 2-week period. However, the gout recurrent rate or gout flare-related inflammation indicators did not change in the febuxostat or control groups. Treatment-related adverse events were mild and similar between groups.</p><p>Conclusion: Initiation of the urate-lowering drug febuxostat during an acute gout attack caused no significant difference in daily pain, recurrent flares, or adverse effects. The treatment significantly decreased SU levels in the early stage and might have potential long-term benefits in these patients.</p>
rheumatology
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to evaluate the effectiveness and safety of starting the uric - acid - lowering drug febuxostat during an acute gout attack. Specifically, the study aims to explore the following issues: 1. **Timing of urate - lowering therapy (ULT)**: Can urate - lowering therapy be initiated during an acute gout attack, or should it be started after the acute symptoms have subsided? 2. **Efficacy and safety of febuxostat**: Will the immediate use of febuxostat during an acute gout attack affect the patient's daily pain, recurrence rate, inflammatory markers, or cause adverse reactions? 3. **Potential benefits of long - term management**: Will early initiation of urate - lowering therapy help to reach the target serum uric acid (SU) level more quickly and may bring long - term treatment benefits? ### Research background Gout is a disease caused by the accumulation of uric acid due to abnormal purine metabolism, and is characterized by a rapidly developing inflammatory response. Although an acute gout attack is usually self - limiting, many patients stop treatment after the symptoms subside, which may lead to repeated attacks of the disease and even develop into chronic gout. Therefore, optimizing the treatment plan for gout is crucial for improving the prognosis of patients. Currently, there is controversy regarding the timing of initiating urate - lowering therapy during an acute gout attack. Some guidelines recommend starting urate - lowering therapy 1 - 2 weeks after an acute attack to avoid the possible remodeling of micro - tophi caused by a rapid decrease in serum uric acid concentration, which may exacerbate the condition. However, there are also guidelines that recommend starting urate - lowering therapy during an acute attack, especially when anti - inflammatory and analgesic drugs are fully used. ### Research methods To evaluate the effectiveness and safety of using febuxostat during an acute gout attack, the researchers conducted a 12 - week prospective randomized controlled clinical trial. The study subjects were primary gout patients who were hospitalized for the first time due to an acute gout attack. The participants were randomly divided into two groups: - **Febuxostat group**: Took 40 mg of febuxostat daily from the first day of hospitalization. - **Control group**: Started taking 40 mg of febuxostat daily in the third week after the acute attack. All patients received sufficient anti - inflammatory and analgesic treatment. The primary outcome measures included the visual analog scale (VAS) score and the gout recurrence rate, and the secondary outcome measures included inflammatory markers related to gout attacks (such as C - reactive protein, erythrocyte sedimentation rate, IL - 1β, TNF - α) and changes in serum uric acid levels. ### Main findings 1. **Pain score**: During the 14 - day observation period, there was no significant difference in the VAS score between the two groups. 2. **Serum uric acid level**: In the febuxostat group, the serum uric acid level decreased significantly within the first two weeks, and the proportion reaching the target level was higher. 3. **Gout recurrence rate**: There was no significant difference in the gout recurrence rate between the two groups. 4. **Inflammatory markers**: There was also no significant difference in the changes of inflammatory markers between the two groups. 5. **Adverse events**: The incidence of adverse events was similar between the two groups, and all were mild and controllable. ### Conclusions The study shows that initiating febuxostat treatment during an acute gout attack does not exacerbate pain or increase the recurrence rate, nor does it cause significant adverse reactions. On the contrary, this treatment method can reach the target serum uric acid level earlier and may be beneficial for the long - term management of patients. These results support the recommendation of the 2012 American College of Rheumatology (ACR) guidelines that urate - lowering therapy can be initiated during an acute gout attack, provided that sufficient anti - inflammatory and analgesic treatment is given simultaneously. ### Future prospects Although this study provides some important clinical data, larger sample sizes and multi - center studies are still needed to further verify these results and evaluate long - term efficacy and safety. In addition, considering the dose differences of febuxostat in different countries, the dose needs to be adjusted according to specific situations in future clinical applications.